|
Author Question: It is not in the best interests of the researcher to point out the limitations of the research to ... (Read 20 times) |
The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.
When intravenous medications are involved in adverse drug events, their harmful effects may occur more rapidly, and be more severe than errors with oral medications. This is due to the direct administration into the bloodstream.
There are more sensory neurons in the tongue than in any other part of the body.
Cytomegalovirus affects nearly the same amount of newborns every year as Down syndrome.
The FDA recognizes 118 routes of administration.